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 Recent survey data have suggested that 
the prevalence of chronic kidney disease 
(CKD) in the United States is high and has 
increased between 1988 – 1994 and 1999 –
 2004, from 10 to 13 % . 1 Cardiovascular 
morbidity and mortality remain high 
among patients with CKD, and multiple 
observational studies have reported a 
graded increase in the prevalence of car-
diovascular disease and incidence of 
adverse cardiovascular events with 
reduced renal function. Following an 
acute myocardial infarction (MI), patients 
receiving long-term dialysis may have 1- 
and 5-year mortality rates of up to 41 and 
70 % , respectively. 2 In patients with less 
severe renal dysfunction, outcomes fol-
lowing acute MI are likewise poor. 3 
 Multiple mechanisms may be involved 
in the development of worse atheroscle-
rotic disease and increased cardiovascular 
risk in patients with CKD and worse out-
comes a1 er an acute MI. 2 ere is an asso-
ciation between reduced estimated 
glomerular 3 ltration rate and higher prev-
alence of cardiovascular risk factors, and 
it is possible that a higher degree of 
comorbidity and risk factors may explain 
the worse outcome after MI in these 
patients. However, studies have shown 
that renal dysfunction is an independent 
risk factor for adverse cardiovascular and 
mortality outcomes even a1 er adjustment 
for these factors. Prior studies have sug-
gested that clinical outcomes a1 er an MI 
are in8 uenced by the location of the cul-
prit lesion, with worse outcomes noted in 
those with more proximal stenosis. 4 
Plaque distance from the coronary ostium 
appears to be an independent determinant 
of relative lipid content, which is 
potentially associated with plaque 
vulnerability. 5 
 Charytan  et al . 6 (this issue) demonstrate 
that patients with CKD having an MI may 
have more proximal culprit lesions, and 
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 Spatial distribution of coronary 
artery thromboses in patients 
with chronic kidney disease: 
implications for diagnosis and 
treatment 
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 The study by Charytan  et al. provides us with a better understanding of 
the pathophysiology of acute myocardial infarction in patients with 
chronic kidney disease (CKD). One important observation is that more 
proximal plaque rupture results in poorer outcome in patients with CKD; 
clinicians should target these patients for aggressive revascularization 
to try to improve outcomes. This study will hopefully lead to additional 
research and help us develop more effective local and systemic 
therapies for patients with CKD. 
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the location of such lesions may have 
important prognostic implications. 2 is 
interesting study provides us with a new 
insight into the pathobiology of coronary 
artery stenosis and MI in patients with 
CKD. 2 e authors further suggest that dif-
ferences in the distribution and location 
of coronary artery plaque ruptures in 
individuals with CKD could partly explain 
the increased risk associated with this 
condition. 
 2 e observation of proximal clustering 
of ruptured coronary plaques leading to 
MI is not new, and it has been reported 
that such plaques tend to cluster in the 
proximal third of the coronary arteries in 
patients with MI 7 ( Figure 1 ). 2 e di; eren-
tial spatial distribution of such plaques 
with thromboses in patients with and 
without CKD, with plaques located more 
proximally in patients with CKD, is indeed 
a novel observation. What then is the 
implication of this 3 nding for diagnosis 
and treatment of these patients? Com-
puted tomographic angiography has 
evolved significantly and is now an 
e; ective tool for the diagnosis of coronary 
stenosis; it is especially effective for 
proximal narrowings. One recent 
study demonstrated that contrast-
enhanced 64-slice computed tomographic 
angiography is a clinically robust modality 
that allows the identi3 cation of proximal 
coronary lesions with excellent accuracy. 
Measurements of plaque and lumen areas 
derived by computed tomography corre-
lated well with intravascular ultrasound 
(IVUS) in this analysis. 8 Patients with 
CKD may bene3 t from this technology, 
which may obviate the need for diagnostic 
angiography in some patients and will be 
particularly attractive as the amount of 
contrast required for the study diminishes 
with newer-generation scanners. Ulti-
mately, however, outcome studies will be 
needed to determine the utility of this 
technique in patients with CKD. 
 Regarding treatment, we may consider 
treating the proximal portion of the coro-
nary arteries in high-risk individuals such 
as those with CKD with local therapy to 
minimize or eliminate plaque rupture. 
2 e concept of plaque sealing by coronary 
balloon angioplasty has been around 
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3 ltration rate   <  60  ml / min) were rand-
omized to Percutaneous Coronary Inter-
vention with stent implantation or bypass 
surgery, found that event-free survival at 
5 years was 50.7 % in the stent group com-
pared with 68.5 % in the Coronary Artery 
Bypass Gra1 ing  group. 11 Again, a dedi-
cated randomized trial in patients with 
CKD will provide more de3 nitive data 
regarding relative eG  cacy of the revascu-
larization strategies. 
 Finally, the observations by Charytan 
 et al . 6 provide us with a better understand-
ing of the pathophysiology of acute 
MI in patients with CKD. One important 
immediate observation from this study 
is that more proximal plaque rupture 
results in poorer outcome in patients 
with CKD, and clinicians should 
target these patients for aggressive revas-
cularization to try to improve outcomes. 
Although unlikely to in8 uence other cur-
rent treatment strategies in the manage-
ment of patients with CKD presenting 
with MI, I am hopeful that the results 
from this study will lead to additional 
research and help us develop more e; ec-
tive local and systemic therapies that may 
ameliorate the shear forces and plaque 
characteristics in proximal arteries of 
these patients. 
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 Figure 1  | Clustering of ruptured plaques is seen in the proximal portion of the coronary 
arteries in patients with myocardial infarction. This clustering is based on angiographic 
and intravascular ultrasound studies. The areas highlighted in darker blue shade represent the 
vulnerable zones. Abbreviations: LAD, left anterior descending artery; LCx, left circumflex artery; 
RCA, right coronary artery. 
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 Calcium-sensing receptor 
 2 e landmark report by Brown  et al. of the 
cloning and characterization of the cal-
cium-sensing receptor (CaSR) in bovine 
parathyroid glands launched the continu-
ously evolving and exciting story of CaSR 
and calcimimetics. 1 2 e initial characteri-
zation in the parathyroid gland implicated 
the CaSR as an essential element in the 
physiologic machinery responsible for the 
maintenance of calcium homeostasis. 2 e 
CaSR is a 121-kilodalton, low-aG  nity G 
protein-coupled cell-surface receptor that 
senses extracellular levels of calcium ion 
and enables the cell to respond to small 
changes in extracellular ionized calcium 
concentrations. In the chief cells of the 
parathyroid gland, the CaSR regulates the 
secretion of the parathyroid hormone 
(PTH) in response to changes in calcium 
concentrations; small increases in ambient 
calcium concentrations result in signi3 -
cant reduction in PTH. 
 In addition to being present abundantly 
on the surface of the parathyroid cells, the 
CaSR is also present on the calcitonin-
secreting C cells of the thyroid, in multiple 
sites in the kidney, in bone, and in various 
other organ tissues. Activation of the CaSR 
in the thick ascending limb results in sig-
nificant reduction of the paracellular 
transport of the divalent ions calcium and 
magnesium and disturbs the countercur-
rent mechanism, leading to reduction in 
urinary concentration ability. In the inner 
medullary collecting duct, calcium stimu-
lation of the CaSR inhibits the actions of 
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 The new role of calcimimetics as 
vasculotropic agents 
 Ziyad  Al-Aly 1 , 2 
 The discovery of the calcium-sensing receptor (CaSR) and the 
development of calcimimetics have provided new insights into calcium 
homeostasis and new therapeutic opportunities for parathyroid-related 
disorders. However, the CaSR is also implicated in various other cellular 
processes, and the translational applications of calcimimetics may not 
be exclusively calcium-centric. Koleganova  et al. describe a novel role for 
calcimimetics as vasculotropes, which provides the impetus for further 
studies to characterize their effects on vascular biology. 
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vasopressin, leading to increased free water 
clearance and polyuria. Independently of 
its effect on the parathyroid gland, the 
CaSR seems to be involved in the regula-
tion of bone homeostasis; a recent study 
showed that it is critical for chondrogen-
esis and growth plate development. 2 e 
CaSR may also play a PTH-independent 
role in the renal production of calcitriol, 
and gastrointestinal calcium absorption. 
 Beyond its e; ects on calcium homeo-
stasis and water metabolism, the CaSR has 
also been found in multiple organ tissues 
that are not directly implicated in systemic 
calcium regulation, including the intes-
tines, pancreas, brain, heart, and the 
arterial wall ( Figure 1 ). At these sites, 
the CaSR is involved in the regulation of 
peptide and hormonal secretion (insulin, 
gastrin, and vascular endothelial growth 
factor), ion-channel and transporter func-
tion, and a number of important cellular 
processes, such as gene expression, prolif-
eration, di; erentiation, apoptosis, chemo-
taxis, and localization of hematopoietic 
stem cells to the endosteal niche. 
 Calcimimetics 
 2 e discovery of the CaSR facilitated the 
development of calcimimetics, a class of 
agents that modulate the function of the 
CaSR. Type II calcimimetics change the 
structural conformation of the receptor 
and, in the presence of calcium, act as 
positive allosteric modulators of the CaSR, 
rendering it more sensitive to ambient 
calcium concentration and subsequently 
resulting in reduction of PTH secretion in 
a dose-dependant manner. R-568 was the 
3 rst calcimimetic to be tested in clinical 
trials, but because of its low bioavailabil-
ity and numerous interactions with other 
drugs, further clinical testing was not pur-
sued. A second-generation calcimimetic, 
AMG-073 (cinacalcet), was developed and 
shown to have signi3 cant clinical applica-
tions in the management of hypercalcemia 
in patients with parathyroid cancer as well 
as patients with secondary hyperparathy-
roidism on renal replacement therapy. Be-
fore the introduction of calcimimetics in 
clinical practice, most treatment modali-
ties used in the management of second-
ary hyperparathyroidism in patients with 
kidney disease (vitamin D and calcium-
based phosphate binders) resulted in some 
